CD4 and neoplasm: OK-432 plus IL-2 induced autologous tumour-reactive CD4+ Th1 killer lymphocytes, which recognised tumour antigen(s) presented with HLA class II molecules on effusion tumour cells by means of preferential usage of TCRVβ20, and thus possibly contributing to the clinical efficacy of this treatment.